Want to see HK:1952 full AI Analyst Report?
1952 Stock Chart & Stats
HK$51.50
-HK$1.00(-2.24%)
At close: 4:00 PM EST
HK$51.50
-HK$1.00(-2.24%)
Day’s Range― - ―
52-Week RangeHK$22.70 - HK$58.45
Previous CloseN/A
Volume6.86M
Average Volume (3M)7.06M
Market Cap
HK$10.19B
Enterprise ValueHK$8.57B
Total Cash (Recent Filing)HK$2.04B
Total Debt (Recent Filing)HK$1.99B
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Apr 01, 2027EPS Estimate
2.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding354,467,070
10 Day Avg. Volume3,212,992
30 Day Avg. Volume7,062,933
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)2.09
Price to Sales (P/S)6.51
P/FCF Ratio-64.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$54.83Price Target Upside6.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1
Revenue Forecast (FY)HK$3.19B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthRevenue growth of approximately 95% shows a rapid commercial ramp and expanding product contribution. If maintained, this scale can improve operating leverage, broaden the company’s commercial base, and provide a stronger foundation for eventual profitability over the next several quarters.
Healthy Gross MarginA gross margin near 60% indicates solid product-level economics despite the company remaining loss-making. This provides scope for revenue growth to translate into better operating results as commercial scale increases, provided expenses grow more slowly than gross profit.
Moderate LeverageThe sizable equity base and moderate debt-to-equity ratio indicate comparatively limited balance-sheet leverage for a biotech company. This gives Everest greater capacity to fund operations and growth from existing resources while reducing pressure from debt obligations.
Bears Say
Persistent Net LossesThe company has not yet demonstrated sustainable earnings power, as operating and net losses continued in 2025 despite substantial revenue growth. Persistent losses can delay self-funded expansion and may prevent the benefits of scale from reaching shareholders.
Negative Free Cash FlowNegative operating and free cash flow mean the business is still not self-funding its activities. Although cash burn improved materially from 2024, continued outflows could consume balance-sheet resources and increase reliance on external financing if profitability remains delayed.
Negative Return On EquityNegative return on equity across every year shown indicates that the capital base has not yet produced positive shareholder returns. This reflects the company’s ongoing losses and raises the risk that equity capital could be consumed over time without a durable improvement in profitability.
Everest Medicines Ltd. News
1952 FAQ
What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$22.70 and its highest was HK$58.45 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$10.19B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 174 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Aug 18, 2026. The company reported -HK$0.023 earnings per share for the quarter, beating the consensus estimate of -HK$1.087 by HK$1.064.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Undervalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is 2.17.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 354,467,070 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.023 in its last earnings report, beating expectations of -HK$1.087. Following the earnings report the stock price went down -18.716%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Everest Medicines Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.47%
12-Months-Change
Fundamentals
Return on Equity
-1.02%
Trailing 12-Months
Asset Growth
80.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Everest Medicines Ltd.
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
1952 Stock 12 Month Forecast
Average Price Target
HK$54.83
▲(6.47% Upside)
Technical Analysis
Zai Lab Ltd
―
Antengene Corporation Limited
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―